background: Relatively few studies published to date have investigated IVF and cancer risk. In this study we compared the occurrence of cancer in women who gave birth after IVF with all other women who gave birth in the study period.
Introduction
Relatively few studies have been published on the cancer risk of women who have undergone IVF. Studies from Australia (Venn et al., 1995 (Venn et al., , 1999 (Venn et al., , 2001 ) indicated a transient increase in the risk of having breast or uterine cancer diagnosed in the first year after treatment but there was no increase in the overall incidence of breast, ovarian or uterine cancers. It was a suggested increase of uterine cancers (notably sarcomas) in women who were infertile but had not had IVF but it was based on only seven cases. In studies from Israel, Dor et al. (2002) found no evidence of an increased cancer risk after IVF but Lerner-Geva et al. (2003) identified an increased risk for cancer, notably ovarian cancer, but after exclusion of cases which appeared within 1 year after IVF, the risk estimate declined and lost statistical significance. That study was based on a total of 21 cancer cases. A third study from Israel (Pappo et al., 2008) based on 35 breast carcinomas found a possible association with IVF therapy. A specific study of the risk for breast cancer after treatment for infertility, among which about three quarter had fertility drugs (including IVF), found no risk increase (Gauthier et al., 2004) . In a study of 38 women who developed breast cancer after IVF with 114 age-matched women who had IVF but did not develop breast cancer, an increased risk was found in women who were over 30 at the time of IVF treatment (Katz et al., 2008) .
In a previous study from Sweden of women who underwent IVF up to 2001 (Källén et al., 2005) , we found no increased risk for cancer with the exception of the risk for ovarian cancer, which was already increased prior to the first IVF treatment. The risk for cervical cancer was shown to be lower in IVF recipients. Another paper based on more or less the same material had similar findings with respect to cervical and breast cancer (Kristiansson et al., 2007) .
The objective of the present study was to extend the follow-up period of the women who had been treated with IVF and also to add data for births after IVF treatments in 2002-2006. 
Materials and Methods
Women who delivered an infant following IVF treatment (performed 1982-2006 with a delivery in 1982-2007) were identified from reports from all IVF clinics in Sweden (Nygren et al., 2007) and were compared with all other women who gave birth during the period. The study was restricted to women who were recorded in the Swedish Medical Birth Register (National Board of Health and Welfare, 2003) . The personal identification number, which everyone living in Sweden has, was used for linkage with the Swedish Cancer Register (Barlow et al., 2009) . This is a tumour register so a woman can be recorded repeatedly if she has more than one tumour. Both malignant, borderline and some specified benign tumours are included. In this paper, we will use the term 'cancer' to denote all instances equivalent with a tumour reported in the National Cancer Register.
We characterized each woman with the first recorded tumour and the temporal relationship with her first IVF was based on the date of diagnosis of that tumour. Among women who had no IVF treatment, the temporal relationship was based on the first delivery during the study period. The object of the study was thus, for each woman, her first delivery (with or without IVF) during the observation period, related to her possible cancer development. 'Before IVF' indicates a cancer which was identified before the delivery of the first child after IVF and (in the comparison group) before the first delivery during the observation period.
The risk for a cancer was determined by comparison of the occurrence of cancer among women who had been treated with IVF with all other women recorded in the Medical Birth Register, using Mantel-Haenszel estimates of odds ratios (ORs) with 95% confidence intervals (95% CIs) according to Miettinen's method. Two ORs were compared using the Mantel-Haenszel variances.
When the expected number of cancer cases was low (,10), the x 2 which is part of Mantel-Haenszel analysis is not permissible. Instead, we used a risk ratio estimate which is formed as the observed number over the expected number (calculated after the same adjustments as in the OR estimates) and the 95% CI was based on exact poisson distribution. With these low rates, the risk ratio and the OR will be very similar. Year of delivery and maternal age at delivery (5-year classes, ,20, 20-24 etc.) were used as co-variates in the analysis. These two variables also define the birth cohort of the woman. Furthermore, smoking during early pregnancy was adjusted for. Smoking information was obtained by midwife interview in early pregnancy and was categorized as unknown ( 7%), no smoking, smoking ,10 cigarettes per day and smoking ≥10 cigarettes per day.
In studies of cancer risk before the first IVF, comparisons were based on women who had their first delivery during the study period (parity 1), because previous deliveries could otherwise influence cancer risk. Adjustment was made for year of delivery, maternal age and smoking during the pregnancy.
In studies of cancer risk after IVF (or after the first control delivery during the study period), adjustment was made for year of delivery, maternal age, the highest smoking score during the woman's pregnancies and the highest number of infants in any birth (1, 2, 3 or more). If a woman had a cancer before the proband pregnancy, she was not included in the risk study after the IVF.
Specific cancer forms were also studied: breast cancer, cervical cancer, ovarian cancer, placental cancer, malignant melanoma, thyroid cancer, central nervous system (CNS) cancer, colon cancer and all other cancers as one group. Diagnoses were based on ICD and SNOMED (after 1993) codes in the cancer register.
Ethical approval
The study was performed within the responsibilities of the National Board of Health and Welfare and therefore no ethical approval from outside ethical committees was needed.
Results
A total of 24 058 women who had given birth after IVF and a total of 1 394 061 women in the general population were studied using the cancer register. Among the IVF group, 1279 had one or more tumours registered, among the control group 95 775 women had a registered cancer. The cancer diagnoses of the women after IVF are shown in Table I Non-Hodgkin lymphoma 9 9
Multiple myeloma 1 1
Lymphatic leukaemia 6 6
Myeloic leukaemia 6 6 Myelofibrosis 1 1 Thrombocythemia 1 1
Cancers both before and after the first IVF.
one cancer diagnosis, the highest number of repeated cancers referred to breast (n ¼ 17) and cervix (n ¼ 19) cancer. The women were categorized according to the diagnosis of the first cancer and the timing (before/after IVF) referred to that event.
The mean age at the first delivery after IVF was 32.0 years and the mean age at the end of the follow-up was 40.3 years so the average follow-up time was 8.3 years for IVF women. Adjustment was made in the analysis for maternal age and year of birth which means that comparisons between IVF women and reference women were cohort-based.
Among all women who underwent IVF, 86% (18 643) were of parity 1 at the first delivery after IVF. The corresponding figure for the population was 77% (1 094 219) at the first delivery during the observation period.
The cancer risk among first parity women before IVF or before they had their first delivery during the observation period is shown in Table II . There were only three cases of mammary cancer. The risk for most other cancers was increased before IVF compared with other women and the highest OR was for ovarian cancer. If these cases were removed, a significantly high risk remained for other types. Among these women, 49 (6%) had their cancer diagnosis within 1 year before the IVF delivery and 247 (29%) within 5 years before the IVF delivery.
The cancer risk after IVF is shown in Table III . There is a general statistically significant decrease of cancer risk. This is lower in women who had more than one delivery (OR ¼ 0.67, 95% CI 0.59 -0.76) than in women who had only one delivery (OR ¼ 0.94, 95% CI 0.80 -1.09). It did not differ between women who had only singleton deliveries and women who had one or more multiple birth delivery. If women born abroad or of non-Swedish nationality or with a partner of non-Swedish nationality were removed (19% of all), the OR decreased somewhat to 0.71 (95% CI 0.64 -0.79), based on 352 cancers after IVF and 58 568 in the population. When specific cancer types were studied, breast, cervical and placental cancers showed significantly low-risk estimates and ovarian cancer a significantly high-risk estimate.
The reduced risk for breast cancer was stronger if the women had had a multiple birth delivery (OR ¼ 0.33, 95% CI 0.18-0.61) than in women who had singleton deliveries (OR ¼ 0.86, 95% CI 0.68 -1.08) and the two ORs differ significantly (z ¼ 2.19, P ¼ 0.04). The breast cancer risk estimate for women aged 30 or over at IVF treatment was OR ¼ 0.73, 95% CI 0.58 -0.92, based on 79 cases after IVF. Among the 91 women with a breast cancer after IVF, 10 were ,35 years at the cancer diagnosis, 43 were between 35 and 44 years, 29 between 45 and 49 years and 9 between 50 and 54 years.
The majority of cervical cancers diagnosed after IVF treatment (123 among 157 with specified diagnoses) were cancer in situ.
Among the 26 ovarian cancers diagnosed after IVF, there were 6 serous, 1 mucinous, 4 endometrioid, 2 clear cell, 2 granulosa cell, 8 cystadenomas, 1 thecom and 2 unspecified cancer.
Discussion
The present study investigates cancer risk in women who have had an infant after IVF. This is a valuable study as we have been able to access accurate records on a large population over a long follow-up time (up to 26 years). Comparisons are made with the cancer risk in women who gave birth during the observation period without any known IVF with the same age and delivery year. Some of these women may have had other fertility treatments and a very few may have had IVF without this being identified (for example IVF treatment obtained abroad). If fertility treatment affects cancer risk, this will bias the risk estimates towards 1.0. It should be stressed that the study only included women who had a delivery after IVF and the results therefore may not be applicable to women who fail to get pregnant after IVF treatments. A further limitation of the study design is that the calculations are based on the supposition that no women have died or emigrated during the observation period. This is an incorrect assumption; some women have, and therefore the cancer risks will be slightly underestimated. This is of importance only if survival or emigration rate differ between women who have had IVF and other women. There is no evidence that women who had IVF have an increased mortality (Källén et al., 2005) and emigration should be lower among women who had IVF than among other women, because the former are less often born outside Sweden and are therefore less likely to emigrate. In the analysis of the risk for any cancer after IVF, the risk decreased slightly from 0.74 to 0.69 when women born abroad or of non-Swedish nationality or whose partner was of nonSwedish nationality were excluded from the analysis. There is no information available on the cause of infertility in the women undergoing IVF and no information on the use of specific fertility drugs. After the mid-1990s, gonadotrophins only were used in Sweden with IVF, whereas before that time a combination of gonadotrophins and clomiphene was used. In this study it is likely that a proportion of women had been treated , with clomiphene without success, before IVF was tried.
Adjustment was made for year of birth and maternal age (which defines the birth cohort of the woman), the highest parity and the highest smoking score among the pregnancies of the woman (for studies of cancer risk before IVF only first parity women were analysed). As in all epidemiological studies, it is possible that unidentified confounders affected the results and for instance contributed to the low-risk estimates for breast and cervical cancers after IVF.
It is also possible that a subfraction (e.g. women having a specific hormone treatment or women with a specific type of infertility) could have an increased cancer risk which we could not identify.
In most previous studies, comparisons have been made between the cancer risk in women who had IVF and the population risk. We have chosen women who have given birth without known IVF as a comparison group. The reason is that pregnancy itself may influence cancer risk, either as a direct effect on the pregnancy or by selection of women, which may influence cancer risk. Thus, for instance, early age at the first pregnancy and high parity protect against breast cancer risk (Kelsey et al., 1993) while infertility and nulliparity is associated with an increased epithelial ovarian cancer risk (Salehi et al., 2008; Sueblinvong and Carney, 2009) .
There are two possible associations between a cancer event and IVF. Either the cancer or its treatment has caused infertility in the woman, leading to IVF, or the IVF treatment including hormonal stimulation will affect cancer risk after the IVF treatment.
Cancer detected before IVF
We found that the risk of having a cancer increased the risk of needing IVF, seen for most types of cancer but especially high for ovarian cancer. This phenomenon may be due to radiation and chemotherapy leading to ovarian failure (Maltaris et al., 2007; Schmidt et al., 2010) but also to some surgical interventions. An occurrence of IVF after other cervical procedures than conization or ablation has been demonstrated (Jakobsson et al., 2008) . It has also been shown (van Hamont et al., 2006) that women who are treated with IVF have a higher rate of abnormal cervical smears than controls, and another study found a high rate of human papilloma virus among 106 women undergoing IVF (Spandorfer et al., 2006) .
Few IVF pregnancies were preceded by breast cancer. A low rate of pregnancies (3%) after premenopausal breast cancer has been previously demonstrated (Mueller et al., 2003) .
The increased risk of IVF after ovarian cancer may have a number of different explanations. Endometriosis which is linked to infertility and is an indication for IVF and is also associated with an increased risk for endometrioid and clear cell ovarian cancers (Vlahos et al., 2010) . Ovarian pathology may increase both the risk for ovulation disturbances leading to infertility and ovarian cancer risk. Oral contraceptive use is known to decrease the ovarian cancer risk (Rosenberg et al., 1994; Soegaard et al., 2007) and infertile women are less likely than other women to have used oral contraceptives for extended periods. It is likely that the majority of ovarian cancers occurring before IVF were of border-line type as bilateral oophorectomy is usually performed in case of a malignant ovarian cancer.
Also some other cancers appeared to occur at an increased rate before IVF, notably CNS cancers. Whether this is an effect of the disease or of therapy cannot be decided from the present study.
Cancer detected after IVF
The question of cancer risk after IVF treatment is strongly linked to the question of the effect of drugs used for infertility. This has been mainly postulated for breast and ovarian cancers. As pointed out above, pregnancy itself may affect these cancer risks. We found a generally lower than expected risk for any cancer after IVF but this was mainly due to a low risk for breast and cervical cancer. Among non-genital cancers, no clear risk decrease was seen. The risk decline in breast and cervical cancers could be an effect of early detection of precancerous stages as a consequence of a more intense screening.
Breast cancer
Breast cancer is markedly affected by pregnancy factors (Nechuta et al., 2010) . Multiple births seem to decrease the risk for breast cancer (Jianguang et al., 2007) even though a short-term elevation of the risk after a multiple birth has been described (Wohlfahrt and Melbye, 1999) . High fetal growth has been suggested to increase the breast cancer risk (Wohlfahrt and Melbye, 1999; Cnattingius et al., 2005) . Another pregnancy factor which seems to decrease the breast cancer risk is pre-eclampsia and pregnancy-induced hypertension (Nechuta et al., 2010) . Most studies on the effect of fertility drugs on breast cancer risk have concluded that no effect is seen (Venn et al., 2003; Orgéas et al., 2009) . Our data show a protective effect of IVF on breast cancer risk. Pre-eclampsia occurs at an increased rate in IVF pregnancies (Källén et al., 2005) which could contribute to a decreased risk for breast cancer. The high rate of multiple births after IVF will also result in a decreased risk but when women who had had a twin delivery after IVF were compared with other women with a twin delivery (adjusting for year of delivery, age and parity), the breast cancer risk is still lower than expected after IVF. A difference between the two sets of twin pregnancies should be taken into consideration: after IVF the vast majority are dizygotic twins but among spontaneous pregnancies, a considerable proportion are monozygotic. We found a reduced risk of breast cancer also among women who were 30 years or older at delivery which is not in agreement with the results of a previous study (Katz et al., 2008) . It should be noted that the majority of the breast cancer patients were premenopausal at the time of study-only nine were 50 years old or older.
Ovarian cancer
Ovarian cancer is also affected by pregnancy factors. Pregnancy decreases the risk for ovarian cancer but higher maternal age at first pregnancy increases the risk (Soegaard et al., 2007; Salehi et al., 2008; Sueblinvong and Carney, 2009 ). Preterm births resulted in a higher ovarian cancer risk than term pregnancies but multiple births seemed to have no clear effect (Albrektsen et al., 2007; Mucci et al., 2007; Jordan et al., 2009) . High placental weight has been shown to increase the risk for epithelial ovarian cancer (Cnattingius et al., 2008) and intrauterine growth retardation, notably at term birth, decreased it (Mucci et al., 2007) . Use of fertility drugs seems to have little effect on ovarian cancer risk (Crosbie and Menon, 2005) but an increased risk was indicated in some studies ( Jensen et al., 2008; Sanner et al., 2009) .
We found an increased risk for ovarian cancer after IVF. This risk increase is lower than that seen before IVF. The finding is likely an expression of an association between infertility and ovarian cancer and the use of fertility drugs seems to have no effect of its own.
Placental tumours
Placental tumours occurred in only five cases with a markedly low risk. In three of these cancers the SNOMED diagnosis was hydatidiform mole, in one choriocarcinoma, and in one a histological diagnosis was lacking.
Other cancers
In a study comparing cancer rates after fertility drugs with population rates, an increased risk for melanomas was noted, notably after clomiphene use (Althuis et al., 2005) and a study of infertile women exposed to fertility drugs found an increased risk in parous women (Hannibal et al., 2008a ). An increased risk of colon cancer (Althuis et al., 2005) and of thyroid cancer was found in nulliparous women (Althuis et al., 2005) and in parous women after clomiphene (Hannibal et al., 2008b) . In this study we found no significantly increased risk for any of these cancers.
These results agree with the data presented in our previous report (Källén et al., 2005) but statistical significance has now been reached, for instance for a reduced risk of breast cancer.
In conclusion, the results of this investigation are reassuring. Even though cancer is positively associated with IVF when occurring before IVF treatment, no such effect is seen after IVF. The only exception is ovarian cancer but the risk after IVF is lower than that before IVF, both are probably the result of ovarian pathology increasing the risk for both infertility and cancer. As pointed out above, a low use of oral contraceptives by women in infertile couples may also contribute to an increased ovarian cancer risk. It should be underlined that follow-up time is limited and most information refers to cancer risks in premenopausal women.
